Christie Fanton

Vice President, Translational Medicine at Nektar Therapeutics

Christie Fanton has a diverse work experience spanning over multiple companies and roles. Christie is currently working at Nektar Therapeutics as the Vice President of Translational Medicine since May 2022. Prior to this, they held positions as Executive Director, Senior Director, Director, and Associate Director of Translational Medicine at Nektar Therapeutics from 2016 to 2022.

Before joining Nektar Therapeutics, Fanton worked at Nodality Inc., where they served as a Senior Director of Research from 2015 to 2016 and as a Director of Research from 2014 to 2015. Christie managed a group of Ph.D. and non-Ph.D. scientists and successfully led multiple programs, including experimental design, data analysis, report generation, and result presentation to collaborators.

Fanton also worked at Novartis Institutes for BioMedical Research, where they held various roles from 2009 to 2014. Christie served as a Research Investigator III/Translational Biology from 2011 to 2014, leading the development and implementation of patient stratification and indication selection approaches for clinical strategy. Christie also served as a Research Investigator II/Translational Biology from 2009 to 2011, collaborating with colleagues to design, analyze, and validate microarray experiments.

Earlier in their career, Fanton worked at Novartis Institutes for BioMedical Research as a Research Investigator II/Cancer Biology from 2006 to 2008, serving as a lead biologist and project lead for an early-stage small molecule oncology project. Christie also worked at Chiron Corporation as a Scientist II/Research Biology from 2003 to 2006, directing validation studies of small molecule kinase targets for oncology.

Fanton started their career as a Postdoctoral Researcher at UCSF Helen Diller Family Comprehensive Cancer Center from 1998 to 2001.

Christie Fanton completed their Bachelor of Arts degree at Cornell University from 1986 to 1990. Subsequently, from 1992 to 1998, they pursued their PhD at Boston University School of Medicine. The field of study for both degrees is not provided.

Links

Timeline

  • Vice President, Translational Medicine

    May, 2022 - present

  • Executive Director Translational Medicine

    January, 2021

  • Sr Director Translational Research

    December, 2019

  • Director Translational Research

    February, 2018

  • Associate Director Translational Research

    September, 2016

View in org chart